B. Riley began coverage on shares of InfuSystem (NYSE:INFU – Free Report) in a report issued on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $13.00 price objective on the stock.
Separately, StockNews.com upgraded InfuSystem from a buy rating to a strong-buy rating in a research report on Friday, September 20th.
View Our Latest Stock Analysis on INFU
InfuSystem Price Performance
InfuSystem (NYSE:INFU – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $33.70 million during the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%.
Institutional Investors Weigh In On InfuSystem
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kings Path Partners LLC purchased a new stake in shares of InfuSystem in the second quarter worth approximately $514,000. First Eagle Investment Management LLC grew its stake in InfuSystem by 12.7% in the first quarter. First Eagle Investment Management LLC now owns 605,235 shares of the company’s stock worth $5,187,000 after purchasing an additional 68,021 shares in the last quarter. Sequoia Financial Advisors LLC bought a new position in InfuSystem in the second quarter worth approximately $272,000. Squarepoint Ops LLC bought a new position in InfuSystem in the second quarter worth approximately $230,000. Finally, Ranger Investment Management L.P. grew its stake in InfuSystem by 4.7% in the fourth quarter. Ranger Investment Management L.P. now owns 689,842 shares of the company’s stock worth $7,271,000 after purchasing an additional 30,835 shares in the last quarter. 71.13% of the stock is currently owned by hedge funds and other institutional investors.
About InfuSystem
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Featured Articles
- Five stocks we like better than InfuSystem
- What Is WallStreetBets and What Stocks Are They Targeting?
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What Are Some of the Best Large-Cap Stocks to Buy?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- The Risks of Owning Bonds
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.